COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study With Tarceva and Chemotherapy vs. Chemotherapy Alone in Patients With Advanced Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00047736
Recruitment Status : Completed
First Posted : October 17, 2002
Last Update Posted : June 21, 2013
Information provided by (Responsible Party):
Genentech, Inc.

Brief Summary:
The purpose of this study is to determine if Tarceva plus standard chemotherapy is more effective than standard chemotherapy alone in the treatment of lung cancer.

Condition or disease Intervention/treatment Phase
Lung Cancer Drug: Tarceva (erlotinib HCl) Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Masking: Double
Primary Purpose: Treatment
Official Title: A Phase III, Randomized, Double Blind, Multicenter Trial of Tarceva (Erlotinib) Plus Chemotherapy (Carboplatin and Paclitaxel) Versus Chemotherapy Alone in Patients With Advanced (Stage IIIb or IV) Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
Study Start Date : July 2001
Actual Study Completion Date : July 2003

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed informed consent
  • Age >=18 years
  • Histologically documented, unresectable, inoperable, locally advanced, recurrent or metastatic Stage IIIB or Stage IV Non-Small Cell Lung Cancer (NSCLC)
  • A cytologic diagnosis is acceptable (i.e., FNA or pleural fluid cytology)
  • Measurable or non-measurable disease
  • ECOG performance status of 0 or 1
  • Life expectancy of >=3 months
  • >= 3 weeks since any prior surgery or radiotherapy (>=2 weeks for patients who receive <=30 Gy of radiotherapy involving <25% of the marrow reserve)
  • Use of an effective means of contraception (women of childbearing potential)
  • Able to comply with study and follow-up procedures

Exclusion Criteria:

  • Evidence of small cell, carcinoid, or mixed small cell/non-small cell histology
  • Malignancies within 3 years except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer
  • Symptomatic or untreated brain metastases
  • Prior systemic chemotherapy for NSCLC
  • Prior exposure to agents directed at the HER axis (e.g., ZD1839 [Iressa], C225 [Cetuximab], Trastuzumab [Herceptin])
  • Unstable systemic disease, including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, or myocardial infarction within 6 months prior to Day 1, or serious cardiac arrhythmia requiring medication (patients with chronic atrial arrhythmia, i.e., atrial fibrillation or paroxysmal supraventricular tachycardia, are eligible)
  • History of other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the patient at high risk from treatment complications
  • Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous (IV) alimentation, or prior surgical procedures affecting absorption
  • Pregnancy or lactation

Any of the following abnormal baseline hematologic values:

  • Granulocytes count <=1500/uL
  • Platelet count <100,000/uL

Any of the following abnormal baseline liver function tests:

  • Serum bilirubin >1.5× upper limit of normal (ULN)
  • Serum ALT and AST >=2.5× ULN (>5× ULN if due to liver metastases)
  • Alkaline phosphatase >=2.5× ULN

Other baseline laboratory values:

  • Serum creatinine >1.5× ULN or creatinine clearance <60 mL/min
  • Uncontrolled hypercalcemia (>11.5 mg/dL)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00047736

Layout table for location information
United States, Colorado
Multinational Sites
Denver, Colorado, United States
Trial Information Center
Denver, Colorado, United States
Sponsors and Collaborators
Genentech, Inc.
Publications of Results:
Layout table for additonal information
Responsible Party: Genentech, Inc. Identifier: NCT00047736    
Obsolete Identifiers: NCT00029016
Other Study ID Numbers: OSI2298g
First Posted: October 17, 2002    Key Record Dates
Last Update Posted: June 21, 2013
Last Verified: June 2013
Keywords provided by Genentech, Inc.:
Non-small cell lung cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Erlotinib Hydrochloride
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action